Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
62 hedge funds and large institutions have $106M invested in Clearside Biomedical in 2016 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 20 increasing their positions, 6 reducing their positions, and 1 closing their positions.
3,200% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 1
233% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 6
107% more funds holding
Funds holding: 30 → 62 (+32)
3.22% more ownership
Funds ownership: 0% → 3.22% (+3.2%)
23% less capital invested
Capital invested by funds: $138M → $106M (-$31.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$5.78M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.53M |
| 4 |
O
OrbiMed
New York
|
+$5.02M |
| 5 |
Millennium Management
New York
|
+$4.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.71M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$4.85M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$111K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$92.6K |
| 5 |
JP Morgan Chase
New York
|
-$48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| $29K | +$13.6K | +54 | +32% |
|
|
BA
52
BlackRock Advisors
Wilmington,
Delaware
| $25K | +$44.7K | +178 | +2,967% |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| $24K | -$111K | -442 | -71% |
|
|
SO
54
STRS Ohio
Columbus,
Ohio
| $23K | – | – | – |
|
55
BlackRock
New York
| $18K | +$34.4K | +137 | New |
|
56
Bank of America
Charlotte,
North Carolina
| $16K | +$25.6K | +102 | +510% |
|
57
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $14K | +$26.4K | +105 | New |
|
|
SF
58
Synovus Financial
Columbus,
Georgia
| $13K | +$25.1K | +100 | New |
|
59
Canada Life
Winnipeg,
Manitoba, Canada
| $9K | +$16.8K | +67 | New |
|
60
Legal & General Group
London,
United Kingdom
| $7K | +$13.1K | +52 | New |
|
61
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | +$3.77K | +15 | +115% |
|
62
BNP Paribas Financial Markets
Paris,
France
| $957 | -$3.26K | -13 | -65% |
|
|
63
JP Morgan Chase
New York
| – | -$48K | -185 | Closed |
|
CLSD Hedge Fund Activity: Q4 2016 in Review
62 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2016, worth a combined $106M — down 23% from $138M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new CLSD positions and 1 closed out — a net gain of 32 holders — while 20 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $13.6M. The largest seller was Wellington Management Group, cutting an estimated $6.71M.
- 62 institutional investors held Clearside Biomedical (CLSD) as of Q4 2016, up from 30 in Q3 2016.
- Funds reported $106M of Clearside Biomedical stock for Q4 2016, down 23% quarter-over-quarter.
- 33 funds opened new Clearside Biomedical positions in Q4 2016 and 1 closed out, a net change of +32 holders.
- The largest Clearside Biomedical buyer in Q4 2016 was Fidelity Investments, an estimated $13.6M added.
- The largest Clearside Biomedical seller in Q4 2016 was Wellington Management Group, an estimated $6.71M sold.
Based on aggregated 13F filings for Q4 2016.